Ignite Creation Date:
2024-05-05 @ 12:06 PM
Last Modification Date:
2024-10-26 @ 9:20 AM
Study NCT ID:
NCT00242580
Status:
COMPLETED
Last Update Posted:
2016-03-31
First Post:
2005-10-19
Brief Title:
A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Study Overview
Official Title:
A 24-month Randomized Double-masked Sham Controlled Multicenter Phase IIIB Study Comparing Photodynamic Therapy With Verteporfin Visudyne Plus Two Different Dose Regimens of Intravitreal Triamcinolone Acetonide 1 mg and 4 mg Versus Visudyne Plus Intravitreal PegaptanibMacugen in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration
Status:
COMPLETED
Status Verified Date:
2016-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
VERITAS
Brief Summary:
To evaluate the safety and efficacy of the combination treatments in wet age-related macular degeneration The combination treatment consists of verteporfin photodynamic therapy and either triamcinolone acetonide or pegaptanib added as an intravitreal injection
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None